Advertisement
One poster will present Phase 1 multi-dose clinical results for CEM-101, a next-generation oral and intravenous macrolide. Four additional presentations on CEM-101 will present results on the compound's in vitro activity against a variety of bacterial pathogens, including drug-resistant strains. A sixth poster will present in vitro activity of TAKSTA (CEM-102) against European gram positive isolates, including staphylococci, streptococci and enterococci. TAKSTA (sodium fusidate) is a highly active antibiotic against methicillin-resistant Staphylococcus aureus (MRSA). It is in development in the U.S. for acute bacterial skin structure infections (aBSSI) employing a proprietary front-loading oral dosing regimen. All six posters will be presented during the poster session scheduled for 12:30 to 1:30 p.m. CET on Sunday, April 11.
Advertisement
Cempra Pharmaceuticals ECCMID 2010 Schedule At-A-Glance
Sunday, April 11, 2010
Time: On display 12:30 to 13:30 p.m. CET, Poster # 901
R. Jones, D. Farrell, H. Sader, M. Stilwell, M. Castaheira (JMI Laboratories, North Liberty, IA, USA)
Time: On display 12:30 to 13:30 p.m. CET, Poster # 902
J.G. Still, K. Clark, T. Degenhardt, D. Scott, P. Fernandes (Cempra Pharmaceuticals, Chapel Hill, USA)
Time: On display 12:30 to 13:30 p.m. CET, Poster # 903
J. Dubois(1), P. Fernandes(2) ((1)M360, Sherbrooke, Canada, (2)Cempra Pharmaceuticals Inc., Chapel Hill, USA)
Time: On display 12:30 to 13:30 p.m. CET, Poster # 904
J. Dubois(1), P. Fernandes(2) ((1)M360, Sherbrooke, Canada, (2)Cempra Pharmaceuticals Inc., Chapel Hill, USA)
Time: On display 12:30 to 13:30 p.m. CET, Poster # 905
R. Jones, D. Biedenbach, L. Woosley, G. Gerken, M. Castaheira (JMI Laboratories, North Liberty, IA, USA)
Time: On display 12:30 to 13:30 p.m. CET, Poster # 906
M. Castanheira, D. Farrell, M. Janechek, R. Jones
(JMI Laboratories, North Liberty, IA, USA)
About CEM-101
CEM-101 is a next generation macrolide with a number of attributes that may provide clinically important advantages over several comparator products:
The annual incidence for pneumonia in the United States is over 5 million patients each year. There is a growing need for new drugs to address the issues of drug resistance, tolerability, and administration associated with currently available treatments. Cempra has licensed exclusive worldwide rights from Optimer Pharmaceuticals, Inc., except in the Association of Southeast Asian Nations (ASEAN) countries, to discover, develop and commercialize macrolides from a library of more than 500 compounds from Optimer's OPopS drug discovery platform.
About TAKSTA(TM)
TAKSTA, (sodium fusidate) is a novel class of antibiotic with an established history of safety and efficacy outside the United States. TAKSTA is being developed as an NCE in the U.S. for aBSSI. Clinical trials with TAKSTA employ a proprietary front-loading oral regimen designed to increase potency, increase coverage and minimize resistance development. Cempra believes that TAKSTA will be an important addition to anti-MRSA therapies based on the following:
About 60 to 80 percent of the 13 million acute skin structure infections that occur in the U.S. each year are infected with MRSA. There is a growing need for an oral anti-MRSA drug that is safe, effective and is capable of long-term administration.
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.
-- Poster presentation: "CEM-101, a novel fluoroketolide, tested against European clinical isolates from 2009 (first-year surveillance results)"
SOURCE Cempra Pharmaceuticals
